June 2026 Research Update

Across these papers, a consistent pattern was that staging and confirmation of Langerhans cell histiocytosis (LCH) often benefits from combining different tools rather than relying on a single test. Whole-body imaging that shows active disease helped map where LCH is present, while biopsies and lab testing supported diagnosis when imaging alone could look like other conditions. [1] [2] [3] [4] [5]

In a retrospective study of 148 people with pathologically confirmed LCH, 18F-FDG PET/CT (a scan that highlights metabolically active disease) identified more disease sites than CT or MRI and changed disease classification in some patients. The same study also reported that a modified PET/CT response scoring approach (mPERCIST) labeled far more lesions and patients as measurable than older measurement rules, which can affect whether someone meets imaging requirements for research studies. [1]

For lung involvement, a retrospective series of pulmonary inflammatory myeloid neoplasms (including pulmonary LCH) reported that transbronchial lung cryobiopsy provided a diagnosis in most cases, while surgical lung biopsy diagnosed all cases in that series. The study also noted that genetic testing was feasible in some cryobiopsy samples and identified MAPK-pathway mutations in a subset, and that higher cyst burden on chest CT was linked with worse breathing test results. [2]

Two case reports in 2-year-old boys highlighted how LCH can be difficult to recognize when it appears in specific places. One described lung LCH diagnosed using imaging plus lung tissue testing and genetic testing, in the setting of ongoing respiratory symptoms and fever. [4]

Another case report described LCH involving the dura (the lining around the brain), where imaging could resemble a meningioma or inflammatory thickening of the dura. In that single patient, MRI showed structural detail while FDG-PET showed disease activity, and using both together was described as helpful for recognition and central nervous system staging. [3]

For liver involvement in pediatric multisystem LCH, one small retrospective study described liver biopsy appearance and tested a computer model to separate hepatic LCH from look-alike conditions on biopsy images. The model showed very high overall discrimination (AUC 0.99) but had low sensitivity (33.3%), meaning it missed some cases in this small dataset even though it was highly specific (100%). [5]

One pediatric chart review of transfusion-dependent anemia showed that LCH can appear among a wide range of non-hemoglobin-related causes of severe anemia in children. In that context, the authors emphasized the need for a structured diagnostic workup to distinguish these less common causes from more typical blood disorders. [6]

For patients and caregivers, these studies mainly add background on why LCH diagnosis and staging can involve multiple steps, especially when the lungs, liver, or central nervous system are involved or when symptoms overlap with other diseases. The strongest evidence here is the larger retrospective PET/CT study, suggesting this scan may reveal additional areas of disease and may affect how measurable disease is defined for clinical trials, but it does not by itself define what any one person needs. Smaller organ-specific studies and single-patient reports underline ongoing uncertainty about the best approach in rarer presentations, and early computer-based tools for biopsy interpretation are still exploratory.

In these small, mainly descriptive reports in children, Langerhans cell histiocytosis (LCH) showed up in many different skin and nail ways, and these visible changes sometimes came before the full extent of disease was recognized. Overall, the papers reinforce that biopsy of skin or nail tissue (using specific lab stains) can help confirm LCH, and that skin and nail involvement may occur alongside disease in other parts of the body. Because these are case reports and small series, they describe patterns seen in limited numbers of patients and cannot show how often any one sign happens in the broader LCH population. [7] [8] [9]

In a 10-child series from a dermatology center, 8 children had skin involvement and 5 had nail involvement, with nail changes described as varied rather than one single typical pattern. All children in this series had multisystem disease, most often involving skin and bone, and the time to diagnosis ranged from 2 months to 3 years, showing how LCH skin and nail changes can be missed or mistaken for other problems. Biopsies repeatedly showed characteristic LCH cells and were supported by positive staining for markers such as CD1a, CD207 (Langerin), and S100. [7]

Two additional pediatric cases highlighted that nail changes can be the first noticeable sign that leads to a broader evaluation. One child had single-system disease with mild lymph node enlargement and tested negative for BRAFV600E, while the other had multisystem disease involving bone and lungs, confirmed by nail bed, skin, and bone biopsies. Both children received systemic chemotherapy and were reported to have improvement, including metabolic inactivity in one case at 9 months. [8]

A separate case report in a 3.5-month-old infant described vesiculopustular skin lesions along with significant lung involvement and breathing distress. When lung testing was not diagnostic, a skin biopsy with positive CD1a, S-100, and CD68 staining confirmed LCH, showing that skin findings can provide a practical path to diagnosis even when internal-organ testing is challenging. After systemic corticosteroids and respiratory support, the report described marked clinical improvement and near-complete resolution on follow-up chest imaging. [9]

For families living with LCH, these papers mainly serve as background on why clinicians pay close attention to rashes and nail changes: in some children, these visible signs were part of multisystem LCH or were the first clue that led to confirming the diagnosis by biopsy. What remains uncertain from this evidence is how common specific nail or skin patterns are, or which exact changes reliably point to more widespread disease, because the reports are small and come from specialized settings. [7] [8] [9]

Across two retrospective studies, targeted medicines aimed at the MAPK pathway (such as BRAF and MEK inhibitors) were linked to improvement in many patients with Langerhans cell histiocytosis (LCH), including those with neurodegenerative brain involvement, as well as adults in mixed histiocytic conditions that included LCH. These studies also showed that side effects were frequent and sometimes led to dose changes or stopping treatment. Because the evidence came from retrospective cohorts, it cannot fully answer how these medicines compare with other treatments or what the best timing and duration should be. [10] [11]

In a European multicenter cohort of 60 children with neurodegenerative LCH treated with MAPK inhibitors, more than half of clinically evaluable patients improved in symptoms, and about three-quarters improved on brain MRI scans. A minority had progression on either clinical measures or MRI, and the reported 5-year progression-free survival after starting these medicines was high. Side effects were reported in about half of patients and included some severe events, with some children needing dose reductions or stopping therapy. [10]

In a UK multicenter cohort of 37 adults with histiocytic neoplasms (including LCH) treated with the MEK inhibitor trametinib (alone or with dabrafenib), most patients had clinical improvement and many also improved on scans during a median follow-up of about 21 months. Side effects were common, including skin and stomach or bowel symptoms, and some patients stopped treatment due to severe toxicity; two early deaths were reported in very ill patients (including one with end-stage lung LCH). The study also described different non-response rates between trametinib alone and trametinib plus dabrafenib, but it was not designed to prove which approach is better. [11]

A single-patient report highlighted that targeted therapy choices can be complicated when more than one histiocytic disease is present over time. In this 69-year-old woman diagnosed first with LCH and later with Erdheim-Chester disease with a BRAF V600E mutation, one BRAF inhibitor (vemurafenib) was stopped due to intolerance, and a switch to dabrafenib plus trametinib was followed by clinical improvement. As a case report, this experience may not apply to others, but it illustrates both potential benefit and tolerability challenges with targeted therapy. [12]

For patients and caregivers, these papers add detail about real-world use of targeted MAPK-pathway medicines in LCH, especially for neurodegenerative brain involvement in children, and show that improvements on symptoms and scans are often reported. They also underline that side effects are common and sometimes require interruptions or stopping treatment, which is important context for understanding what has been observed so far. What remains uncertain from these studies is how these medicines compare with other options, who benefits most, and the best long-term plan, because the evidence here was retrospective and included mixed patient groups. [10] [11] [12]

One case report described a surgical approach for LCH limited to a rib lesion, focusing on the procedure and recovery rather than comparing surgery to other treatments. The report suggests that, in carefully selected situations, removing a localized bone lesion can be feasible and may lead to an uncomplicated short-term recovery. However, because this was a single patient, it does not show how often this approach works, how it compares with non-surgical options, or what outcomes look like in other organs or more widespread disease. [13]

In a 34-year-old man with LCH involving the right second rib, thoracoscopic resection through a periareolar incision was performed after imaging showed bone destruction with high tracer uptake on PET-CT. Pathology confirmed LCH with negative surgical margins, and the patient recovered without complications, reporting cosmetic satisfaction at follow-up. The report mainly informs what one minimally invasive rib surgery experience looked like, not what should be expected for most patients. [13]

This report is most relevant as background information for people learning about treatment approaches for a single, accessible bone lesion, where surgery may sometimes be part of care. It does not address treatment of LCH that affects multiple sites, the lungs, or the brain, and it cannot predict longer-term outcomes because it describes one person with a short follow-up. More research would be needed to understand when surgery is used most often and how it compares with other ways of managing bone LCH. [13]

Across this research, the key pattern was that how well the liver works mattered more than how big it looks. Children whose liver was enlarged but still working normally generally did well, while children with clear signs of liver dysfunction had far worse outcomes, especially when early treatment response was poor. [14]

In a retrospective study of 80 children with multisystem Langerhans cell histiocytosis (LCH) and liver involvement, liver dysfunction strongly predicted initial treatment failure. Five-year overall survival was 39.4% with liver dysfunction versus 92.6% with enlarged liver but preserved function, and five-year event-free survival was 12.9% versus 70.4%. [14]

Not improving by week 6 of treatment was the only independent predictor of worse overall survival and event-free survival, meaning early response carried important information beyond liver category alone. Low albumin in the blood was also linked to worse event-free survival, suggesting that certain lab signs of liver stress or poor nutrition/reserves may mark higher risk. [14]

Among children with an enlarged liver but preserved function, outcomes were favorable and were not significantly changed by whether the liver was mildly versus massively enlarged when measured by ultrasound-based size scores. In this study, a bile-duct related complication (sclerosing cholangitis) did not clearly change survival within the liver-dysfunction group, and a small number of patients required liver transplantation. [14]

For families, this study helps explain why two children can both be described as having liver involvement in LCH but have very different outlooks: an enlarged liver with normal liver function tests and normal liver performance may not carry the same risk as liver dysfunction. These results are most useful as context for understanding how doctors describe risk and why early treatment response is watched closely; they do not by themselves predict what will happen for any one child. Uncertainty remains because the study was from one center, looked back over past records, and relied heavily on ultrasound (with limited advanced imaging and no molecular testing), so the same patterns should be confirmed in other settings. [14]

Across two single-patient reports, Langerhans cell histiocytosis (LCH) showed up as a localized growth in the gastrointestinal tract rather than widespread disease. In both cases, the diagnosis depended on looking at tissue under the microscope and using special staining tests, and doctors then checked for disease in other organs and did not find it. Because these are isolated reports, it is still uncertain how often LCH presents this way, how long follow-up should be, and how often it comes back after removal. [15] [16]

In one report, a 53-year-old man had rectal bleeding and was found to have a rectal polyp that turned out to be LCH on pathology, with staining positive for markers used to confirm LCH (including S100 and CD1a). After a workup, there was no evidence that any other organ was involved, and the polyp was removed endoscopically. This case highlights that rectal bleeding can sometimes be linked to a very localized LCH lesion found during colonoscopy. [15]

In another report, a man in his 50s had upper-abdominal discomfort after meals and was diagnosed with a solitary stomach LCH lesion on biopsy, with staining confirming LCH and a BRAF V600E gene change reported in the lesion. After a team discussion, the lesion was removed by a specialized endoscopic technique, with clear margins and no complications, and he remained symptom-free with no sign of return at about 10 months. This case suggests that, at least sometimes, stomach LCH can be fully removed endoscopically when it appears limited to one spot. [16]

For patients and caregivers, these reports are mainly background information showing that LCH can rarely appear as a single polyp-like lesion in the stomach or rectum in adults, sometimes causing symptoms like bleeding or discomfort. They also show that doctors may look carefully for disease elsewhere in the body when LCH is found in the gut, because the key question is whether it is truly limited to one site. What remains uncertain is how common these isolated gut lesions are, which patients are most likely to have them, and the long-term chance of recurrence after endoscopic removal, since both publications describe only one person each and follow-up was limited.

Across these papers, Langerhans cell histiocytosis (LCH) was connected to rare but serious events outside typical LCH symptoms: a second, distinct blood cancer in one adult and secondary hemophagocytic lymphohistiocytosis (HLH) in a small group of children. The overall message is that new, severe systemic illness or new skin and blood problems can sometimes signal a different condition in addition to, or separate from, LCH. The evidence is limited because one study is a single-patient report and the other is a small, single-center retrospective cohort. [17] [18]

In one case report, a 78-year-old woman developed blastic plasmacytoid dendritic cell neoplasm (BPDCN) after a prior diagnosis of LCH. Testing suggested the two tumors were biologically different: the LCH sample was BRAF V600E positive, while the BPDCN sample was BRAF V600E negative and c-Myc positive. The patient died from septic shock due to a urinary tract infection before planned chemotherapy could be started, showing how severe infections can rapidly complicate care in frail patients with blood-related cancers. [17]

In a retrospective cohort of 16 children with secondary HLH, one child had HLH triggered by LCH. Most children (93.8%) had fever and low blood counts, and very high ferritin (a blood marker of inflammation) was present in every case. Overall survival was 87.5%, with no deaths in infection-triggered HLH, while deaths occurred in higher-risk, non-infection HLH including a refractory LCH-triggered case. [18]

For patients and caregivers, these studies mainly serve as background about uncommon but serious complications that can occur in the wider landscape of LCH care. The adult case report cannot tell how often a second cancer like BPDCN happens after LCH, but it illustrates that new lesions or new blood and bone marrow problems may reflect a separate disease process with different biology. The pediatric HLH study suggests that when HLH is triggered by conditions other than infection, including LCH, outcomes may be worse, but the numbers were very small and care varied, so the exact risk in LCH remains uncertain. [17] [18]

Across these papers, the main pattern was that several rare conditions can look similar to parts of Langerhans cell histiocytosis (LCH), especially when symptoms involve cysts in the lungs, unusual skin masses, or bowel blockage. Larger registry data helped describe how often different rare lung diseases occur and how outcomes differ, while single-patient reports showed how Rosai-Dorfman disease can appear outside of lymph nodes and create diagnostic confusion. [19] [20] [21]

In a Korean nationwide registry of 304 people with rare interstitial lung diseases, pulmonary Langerhans cell histiocytosis (PLCH) made up 13.2% of cases, and collapsed lung at diagnosis was especially common in some other cyst-forming conditions (44.6% in Birt-Hogg-Dube syndrome and 11.6% in lymphangioleiomyomatosis). Mortality differed by disease type, with pleuroparenchymal fibroelastosis having the highest reported mortality at 26.3% over a median follow-up of 69.5 months, while treatment approaches varied widely by diagnosis. [19]

A separate multicenter study in 50 people with hairy cell leukemia (a rare blood cancer) reported that 12 patients (24%) had at least one lung cyst on high-resolution chest CT, and the cysts were described as thin-walled without nodules or cavitation. The authors noted smoking did not appear to explain cyst number, and they discussed a possible link between a common mutation in this leukemia (BRAFV600E) and cyst formation, but there was no lung tissue testing to prove the cause. [22]

Two case reports showed Rosai-Dorfman disease presenting in uncommon ways that could mimic other conditions. One patient had a purely skin-based disease that formed an infiltrative mass on the nose with deeper skeletal muscle involvement, confirmed by biopsy and immune-marker testing (including S100 positive and CD1a negative). [20]

Another patient had Rosai-Dorfman disease limited to the small bowel (distal ileum), where capsule endoscopy found an ulcerated narrowing that led to capsule retention and bowel obstruction requiring surgery; pathology confirmed Rosai-Dorfman disease and ruled out IgG4-related disease. This illustrates that Rosai-Dorfman disease can rarely present as an isolated intestinal blockage rather than swollen lymph nodes. [21]

For patients and caregivers, these studies are mainly background information showing why symptoms like lung cysts, sudden collapsed lung, unusual skin masses, or bowel obstruction sometimes lead clinicians to consider diagnoses beyond LCH. The strongest evidence here comes from the lung registry describing how different rare lung diseases behave over time, while the Rosai-Dorfman reports describe single individuals and may not apply to others. What remains uncertain is how often shared pathway changes (like BRAFV600E) truly drive similar lung changes across different diseases, because the leukemia study did not include lung biopsy proof.